Summary
Two groups of 6 patients with Parkinson's disease were treated: (Group A) with L-DOPA for 65 days, or (Group B) with L-DOPA+Ro 4-4602 for 30 days. At stated intervals, both groups underwent clinical evaluation, lumbar puncture and measurement of L-DOPA in plasma. A significant improvement in total disability (Webster scale) and akinesia was observed in both groups, but rigidity was improved only in Group B. HVA in CSF increased from its low basal value much more in Group A than in B; 5-HIAA did not change. L-DOPA curves in plasma were similar in the two groups. Baseline Webster scale and akinesia were inversely correlated with basal HVA in all 12 patients. Basal HVA was also inversely correlated with the same clinical parameters evaluated at the end of the trial in all patients. Furthermore, L-DOPA peaks were directly related to CSF HVA level and to improvement (W. R. S. and akinesia) only in patients receiving the combined treatment (Group B). It was concluded that in parkinsonian syndromes clinical improvement was inversely related to severity of the illness and basal HVA in CSF, independent of the type of treatment; treatment with L-DOPA+Ro 4-4602 gave better clinical results than L-DOPA alone, and it restored CSF HVA to a more normal level; the combination with Ro 4-4602 made it possible to administer only one fifth of the quantity of L-DOPA and still to obtain the same L-DOPA level in plasma with better clinical results; and, in patients treated with L-DOPA+Ro 4-4602, the L-DOPA plasma peak was directly related to CSF HVA, Webster scale and akinesia. This means that, once peripheral decarboxylation of L-DOPA has been abolished, plasma levels are very important for L-DOPA availability in the brain.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Algeri, S., Cerletti, C.: Effects of L-DOPA administration on the serotoninergic system in rat brain: correlation between levels of L-DOPA accumulated in the brain and depletion of serotonin and tryptophan. Europ. J. Pharmacol.27, 191–197 (1974)
Algeri, S., Ruggieri, S., Miranda, F., Casacchia, M., Morselli, P.L., Agnoli, A.: Lack of relationships between the plasma levels of L-DOPA and the therapeutic effect in Parkinson's disease treated with L-DOPA. Europ. Neurol. In press (1976)
Barbeau, A.: Treatment of Parkinson's disease with L-DOPA and Ro 4-4602: Review and present status. In: Advances in neurology (ed. D. B. Calne), vol. 2, pp. 173–198. New York: Raven Press 1973
Barbeau, A., Mars, H., Gillo-Joffroy, L.: Adverse clinical side effects of levodopa therapy. In: Contemporary neurology, vol. 8, Recent advances in parkinson's disease (eds. F. H. McDowell, C.H. Markham) pp. 203–237. Philadelphia: F. A. Davis 1971a
Barbeau, A., Gillo-Joffroy, L., Mars, H.: Comparative study of DOPA alone or associated with Ro 4-4602. In: Monoamines, moyaux gris centraux et syndrome de parkinson (eds. J. de Ajuriaguerra, G. Gauthier) pp. 451–454. Paris: Masson et Cie 1971b
Bartholini, G., Burkard, W. P., Pletscher, A., Bates, H. M.: Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature (Lond.)215, 852–853 (1967)
Bartholini, G., Tissot, R., Pletscher, A.: Brain capillaries as a source of homovanillic acid in cerebrospinal fluid. Brain Res.27, 163–168 (1971)
Bernheimer, H., Birkmayer, W., Hornykiewicz, O.: Homovanillinsäure im liquor cerebrospinalis: Untersuchungen beim Parkinson-Syndrom und anderen Erkrankungen des ZNS. Wien. klin. Wschr.78, 417–419 (1966)
Birkmayer, W.: Experimentelle Ergebnisse über die Kombinationsbehandlung des Parkinson-Syndroms mit L-DOPA und einem Decarboxylasehemmer (Ro 4-4602). Wien. klin. Wschr.81, 677–679 (1969)
Butcher, L. L., Engel, J.: Behavioral and biochemical effects of L-DOPA after peripheral decarboxylase inhibition. Brain Res.15, 233–242 (1969)
Campanella, G., Pennetta, R.: La nostra esperienza nel trattamento del morbo di Parkinson con l'associazione L-DOPA + Ro 4-4602. Acta neurol. (Napoli)29, 252–263 (1974)
Casati, C., Agnoli, A., Jori, A., Dolfini, E.: On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease. Z. Neurol.204, 149–154 (1973)
Chang, C. C.: A sensitive method for spectrophotofluorometric assay of catecholamines. Int. J. Neuropharmacol.3, 643–649 (1964)
Everett, G. M., Borcherding, J. W.: L-DOPA effect on concentrations of dopamine, nerepinephrine, and serotonin in brains of mice. Science168, 849–850 (1970)
Giacalone, E., Valzelli, L.: A spectrofluorometric method for the simultaneous determination of 2-(5-hydroxyndol-3-yl) ethylamine (serotonin) and 5-hydroxyindol-3-yl-acetic acid in the brain. Pharmacology2, 171–175 (1969)
Goodwin, F. K., Brodie, H. K. H., Murphy, D. L., Bunney, W. E. Jr.: Administration of a peripheral decarboxylase inhibitor with L-DOPA to depressed patients. Lancet1970 1, 908–911
Granerus, A.-K., Magnusson, T., Roos, B.-E., Svanborg, A.: Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in Parkinsonism. Europ. J. clin. Pharmacol.7, 105–109 (1974)
Guldberg, H. C., Turner, J. W., Hanieh, A., Ashcroft, G., Crawford, G., Perry, A., Gillingham, F.: On the occurrence of homovanillic acid and 5-hydroxyindol-3-yl-acetic acid in the ventricular cerebrospinal fluid of patients suffering from Parkinsonism. Confin. neurol. (Basel)29, 73–77 (1967)
Johansson, B., Roos, B.-E.: Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's syndrome. Eighth International Congress of Neurology, Vienna 1965
Johansson, B., Roos, B.-E.: 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L-DOPA. Europ. J. clin. Pharmacol.3, 232–235 (1971)
Korf, J., Ottema, S., van der Veen, I.: Fluorometric determination of homovanillic acid in biological material after isolation on Sephadex G-10. Anal. Biochem.40, 187–191 (1971)
Lakke, J. P. W. F., Korf, J., van Praag, H. M.: Predicting response to levodopa. Lancet1971 2, 164–165
Laverty, R., Taylor, K. M.: The fluorometric assay of catecholamines and related compounds: Improvements and extensions to the hydroxyindole technique. Analyt. Biochem.22, 269–279 (1968)
Papeschi, R., Molina-Negro, P., Sourkes, T. L., Bertrand, C., Hardy, J.: Homovanillic acid in the cerebrospinal fluid of Parkinson's and other extrapyramidal diseases. In: L-DOPA and Parkinsonism (eds. A. Barbeau, F. A. McDowell) pp. 236–244. Philadelphia: F. A. Davis 1970a
Papeschi, R., Molina-Negro, P., Sourkes, T. L., Hardy, J., Bertrand, C.: Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson's disease and other dyskinesias. Neurology (Minneap.)20, 991–995 (1970b)
Pullar, I. A., Weddell, J. M., Ahmed, R., Gillingham, F. J.: Phenolic acid concentrations in the lumbar cerebrospinal fluid of Parkinsonian patients treated with L-DOPA. J. Neurol. Neurosurg. Psychiat.33, 851–857 (1970)
Rinne, U. K., Sonninen, V.: Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease. Neurology (Minneap.)22, 62–67 (1972)
Rinne, U. K., Sonninen, V., Sirtola, T.: Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor. Z. Neurol.202, 1–20 (1972)
Rinne, U. K., Sonninen, V., Sirtola, T.: Plasma concentration of levodopa in patients with Parkinson's disease. Response to administration of levedopa alone or combined with a decarboxylase inhibitor and clinical correlations. Europ. Neurol.10, 301–310 (1973)
Van Woert, M. H., Bowers, M. B. Jr.: The effect of L-DOPA on monoamine metabolites in Parkinson's disease. Experientia26, 161–163 (1970)
Webster, D. D.: Clinical analysis of the disability in Parkinson's disease. Mod. Treatm.5, 257–282 (1968)
Weiner, W. J., Klawans, M. L. Jr.: Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease. J. Neurol. Neurosurg. Psychiat.36, 747–752 (1973)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Campanella, G., Algeri, S., Cerletti, C. et al. Correlation of clinical symptoms, HVA and 5-HIAA in CSF and plasma L-DOPA in parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602. Eur J Clin Pharmacol 11, 255–261 (1977). https://doi.org/10.1007/BF00607673
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607673